Tryton Medical, a developer of stents designed to treat bifurcation lesions, has launched Side Branch Stent System in Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the UK.
Tryton Medical said that more than 1,000 patients in Europe have been treated with the Tryton Side Branch Stent System, with more than 500 part of a registry or an investigator-lead clinical trial.
Michael Norell, department of cardiology at The Heart and Lung Centre, Wolverhampton, UK, said: “The Tryton Side Branch Stent System offers solution to a persistent problem, how to treat patients with lesions at or near areas of bifurcation in the coronary circulation, a site vulnerable to high rates of restenosis.
“I have been using the Tryton Side Branch System for more than a year now and have found it to be the ideal solution for these difficult cases. I am excited that the Tryton Stent will now be more widely available to physicians and patients in Europe.”
Greg Davis, president and CEO of Tryton Medical, said: “We are pleased with the positive response from physicians to the Tryton Side Branch Stent System in Europe to date, with more than a thousand patients benefiting from treatment with the Tryton Side Branch System.
“We are thrilled to widen European availability with this launch, and anticipate commercialising in additional countries in the coming weeks.”